BioNTech CEO Ugur Sahin Sells $6.24M in Ordinary Shares Under 10b5-1 Plan

Insider Transaction Overview

BioNTech SE (NASDAQ: BNTX) Chief Executive Officer and 10% Owner Ugur Sahin filed a Form 4 disclosing the sale of 64,000 ordinary shares on September 17 and September 18, 2026, generating gross proceeds of approximately $6.24 million.

Transaction Breakdown

• September 17, 2026: 34,000 ordinary shares sold at a weighted average price of $98.5983 per share ($3,352,342.20 total).
• September 18, 2026: 30,000 ordinary shares sold at a weighted average price of $96.2243 per share ($2,886,729.00 total).
• Aggregate Sales: 64,000 shares for a combined total of $6,239,071.20.

Plan and Holding Details

• Rule 10b5-1 Trading Plan: The sales were pre-scheduled pursuant to a Rule 10b5-1 trading plan adopted on June 3, 2026.
• Remaining Holdings: Following these transactions, Dr. Sahin holds 489,209 ordinary shares directly and 39,218,111 ordinary shares indirectly through Medine GmbH, representing vast ongoing equity ownership in BioNTech.

Significance Assessment

The trading significance is categorized as Low. Although the aggregate transaction amount exceeds $6.2 million, it was conducted systematically under an established Rule 10b5-1 plan and represents less than 0.2% of Dr. Sahin's overall beneficial stake in the company.